Diurnal shares surge 136% on agreed all-cash US takeover
- Diurnal agrees takeover at 144% premium - Major shareholders support the deal- Deal expected to complete in Q4Hormone-deficiency drug specialist Diurnal (DNK:AIM) has agreed an all-cash takeover from US-based neuroscience...
30 August 2022